Amycretin (Zenagamtide) — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Amycretin (Zenagamtide)

Also known as: Zenagamtide, Amycretin

Unimolecular GLP-1 and amylin receptor co-agonist (also calcitonin receptor agonist); incretin-based peptide therapeutic

Research chemicalLast updated: October 19, 2026Based on 11 peer-reviewed studies

What it is

Amycretin is an investigational weight-loss drug being studied in clinical trials for obesity and type 2 diabetes. It works by activating multiple appetite and metabolic hormone pathways at once, producing stronger weight loss than single-target drugs in early trials. Not FDA-approved; currently in Phase 2 clinical development.

The scientific side

Amycretin (now also designated zenagamtide) is a novel, single-molecule co-agonist that simultaneously activates GLP-1 receptors, amylin receptors (AMYR), and calcitonin receptors (CTR) (PMID 42532080; PMID 42532079; PMID 40550231). Its dual/tri-receptor engagement synergistically engages hindbrain-mediated satiety pathways and delays gastric emptying. In preclinical rodent studies, amycretin activated human, mouse, and rat GLP-1, amylin, and calcitonin receptors in cell-based systems; targeted key brain areas regulating food intake; reduced total energy intake by 47% in diet-induced obese (DIO) rats over 21 days; and improved insulin sensitivity and histological hallmarks of metabolic dysfunction-associated steatotic liver disease (MASLD). As a GLP-1 receptor agonist component, it promotes insulin secretion and suppresses glucagon; as an amylin/calcitonin receptor agonist, it induces satiety, suppresses prandial glucagon release, reduces prandial hyperglycaemia, and promotes weight loss through central mechanisms (PMID 41747885; PMID 41344603).

Class: Unimolecular GLP-1 and amylin receptor co-agonist (also calcitonin receptor agonist); incretin-based peptide therapeutic

Administration & storage

Administration
Subcutaneous injectiononce weekly (PMID: 40550231)Subcutaneous injectiononce weekly (PMID: 42532080)Oral tabletonce daily (PMID: 40550229)Oral tabletonce daily (PMID: 42532079)
Storage
No storage conditions for amycretin are described in the reviewed abstracts.
Cautions
Gastrointestinal adverse events (nausea, vomiting, constipation) are the most common treatment-emergent adverse events; they are dose-dependent and were reported to be mostly mild to moderate in severity, increasing in frequency with higher doses (PMID: 40550231; PMID: 40550229).,High-dose oral amycretin and CagriSema had higher GI adverse event rates than subcutaneous formulations in network meta-analysis; only high-dose CagriSema—not amycretin—significantly increased AE-related discontinuation in the same analysis, but data are described as preliminary.,Serious adverse events were reported in 8% of participants receiving subcutaneous zenagamtide across all dose groups in the phase 2 T2DM trial; no deaths occurred.,Serious adverse events were reported in 4% of participants receiving oral zenagamtide in the phase 2 T2DM trial; no deaths occurred.,Amycretin is an investigational agent without confirmed regulatory approval; use outside of clinical trials has not been evaluated for safety. Sterile technique is essential for any subcutaneous injection.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification